Beneficial effects of combinatorial micronutrition on body fat and atherosclerosis in mice

Cardiovascular Research

Volumn 91, Issue 4, 2011, Pages 732-741

  El Kochairi, Ilhem ^a   Montagner, Alexandra ^a,b   Rando, Gianpaolo ^a   Lohmann, Christine ^c,d   Matter, Christian M ^c,d   Wahli, Walter ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b CEMAGREF   (France)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Atherosclerosis; Lipids; Nutrition; PPAR ; Prevention

Indexed keywords

APOLIPOPROTEIN E; LIPOPROTEIN RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRACE ELEMENT; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BODY FAT; LIPID STORAGE; MACROPHAGE; MALE; MOUSE; NONHUMAN; NUTRITIONAL ASSESSMENT; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROGENY; TRIACYLGLYCEROL BLOOD LEVEL; VASCULITIS; WEIGHT GAIN; WHITE ADIPOSE TISSUE;

3T3-L1 CELLS; ADIPOSE TISSUE; ADIPOSE TISSUE, WHITE; ANIMALS; ATHEROSCLEROSIS; BODY WEIGHT; LIVER; MACROPHAGES; MALE; MICE; MICRONUTRIENTS; MUSCLE, SKELETAL; PPAR ALPHA; TRIGLYCERIDES;

EID: 80051980867     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvr146     Document Type: Article

References (38)

1. Reddy JK, Rao MS. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol 2006;290:G852-G858.
2. Qian Y, Fan JG. Obesity, fatty liver and liver cancer. Hepatobiliary Pancreat Dis Int 2005; 4:173-177. (Pubitemid 40790160)
3. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005;96:939-949. (Pubitemid 40712793)
4. Fantuzzi G, Mazzone T. Adipose tissue and atherosclerosis: exploring the connection. Arterioscler Thromb Vasc Biol 2007;27:996-1003. (Pubitemid 46641984)
5. Lemmens VE, Oenema A, Klepp KI, Henriksen HB, Brug J. A systematic review of the evidence regarding efficacy of obesity prevention interventions among adults. Obes Rev 2008;9:446-455.
6. Frisinghelli A, Mafrici A. Regression or reduction in progression of atherosclerosis, and avoidance of coronary events, with lovastatin in patients with or at high risk of cardiovascular disease: a review. Clin Drug Investig 2007;27:591-604. (Pubitemid 47295718)
7. Walden RJ. Micronutrition. Lancet 1995;346:635.
8. Huang TH, Teoh AW, Lin BL, Lin DS, Roufogalis B. The role of herbal PPAR modulators in the treatment of cardiometabolic syndrome. Pharmacol Res 2009;60: 195-206.
9. Omar EA, Kam A, Alqahtani A, Li KM, Razmovski-Naumovski V, Nammi S et al. Herbal medicines and nutraceuticals for diabetic vascular complications: mechanisms of action and bioactive phytochemicals. Curr Pharm Des 2010;16:3776-3807.
10. Bourgeois-Lugand MFY, Wahli W, El Kochairi I, Pradervand S. Composition for regulating lipid metabolism.World Intellectual Property Organization WO 2009/050580: Bioresearch & Partners et al., 2008.
11. Zadravec D, Brolinson A, Fisher RM, Carneheim C, Csikasz RI, Bertrand-Michel J et al. Ablation of the very-long-chain fatty acid elongase ELOVL3 in mice leads to constrained lipid storage and resistance to diet-induced obesity. FASEB J 2010;24: 4366-4377.
12. van Raalte DH, Li M, Pritchard PH, Wasan KM. Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future. Pharm Res 2004;21:1531-1538. (Pubitemid 41184380)
13. Kersten S, Desvergne B, WahliW. Roles of PPARs in health and disease. Nature 2000; 405:421-424. (Pubitemid 30367411)
14. Bessesen DH, Rupp CL, Eckel RH. Trafficking of dietary fat in lean rats. Obes Res 1995; 3:191-203.
15. Holloway GP, Luiken JJ, Glatz JF, Spriet LL, Bonen A. Contribution of FAT/CD36 to the regulation of skeletal muscle fatty acid oxidation: an overview. Acta Physiol (Oxf) 2008;194:293-309.
16. Tordjman J, Guerre-Millo M, Clement K. Adipose tissue inflammation and liver pathology in human obesity. Diabetes Metab 2008;34:658-663.
17. Kaplan M, Aviram M. Oxidized low density lipoprotein: atherogenic and proinflammatory characteristics during macrophage foam cell formation. An inhibitory role for nutritional antioxidants and serum paraoxonase. Clin Chem Lab Med 1999;37: 777-787. (Pubitemid 29471943)
18. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr. et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb Vasc Biol 1995;15:1512-1531.
19. Fujioka Y, Ishikawa Y. Remnant lipoproteins as strong key particles to atherogenesis. J Atheroscler Thromb 2009;16:145-154.
20. Mancini FP, Lanni A, Sabatino L, Moreno M, Giannino A, Contaldo F et al. Fenofibrate prevents and reduces body weight gain and adiposity in diet-induced obese rats. FEBS Lett 2001;491:154-158. (Pubitemid 32172021)
21. Duval C, Muller M, Kersten S. PPARalpha and dyslipidemia. Biochim Biophys Acta 2007; 1771:961-971.
22. Hajri T, Abumrad NA. Fatty acid transport across membranes: relevance to nutrition and metabolic pathology. Annu Rev Nutr 2002;22:383-415. (Pubitemid 35221466)
23. Holloway GP, Bonen A, Spriet LL. Regulation of skeletal muscle mitochondrial fatty acid metabolism in lean and obese individuals. Am J Clin Nutr 2009;89:455S-462S.
24. Helge JW, Stallknecht B, Richter EA, Galbo H, Kiens B. Muscle metabolism during graded quadriceps exercise in man. J Physiol 2007;581:1247-1258. (Pubitemid 46887991)
25. Coyle EF. Fat oxidation during whole body exercise appears to be a good example of regulation by the interaction of physiological systems. J Physiol 2007;581:886. (Pubitemid 46887965)
26. Marx N, Sukhova GK, Collins T, Libby P, Plutzky J. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999;99:3125-3131. (Pubitemid 29289077)
27. Nawa T, Nawa MT, Cai Y, Zhang C, Uchimura I, Narumi S et al. Repression of TNF-alpha-induced E-selectin expression by PPAR activators: involvement of transcriptional repressor LRF-1/ATF3. Biochem Biophys Res Commun 2000;275:406-411.
28. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-126.
29. Zandbergen F, Plutzky J. PPARalpha in atherosclerosis and inflammation. Biochim Biophys Acta 2007;1771:972-982.
30. Dashwood MR, Tsui JC. Endothelin-1 and atherosclerosis: potential complications associated with endothelin-receptor blockade. Atherosclerosis 2002;160:297-304. (Pubitemid 34159321)
31. Carone BR, Fauquier L, Habib N, Shea JM, Hart CE, Li R et al. Paternally induced transgenerational environmental reprogramming of metabolic gene expression in mammals. Cell 2010;143:1084-1096.
32. Barker DJ, Gluckman PD, Godfrey KM, Harding JE, Owens JA, Robinson JS. Fetal nutrition and cardiovascular disease in adult life. Lancet 1993;341:938-941. (Pubitemid 23109122)
33. Lanigan J, Singhal A. Early nutrition and long-term health: a practical approach. Proc Nutr Soc 2009;68:1-8.
34. Lombard CB, Deeks AA, Teede HJ. A systematic review of interventions aimed at the prevention of weight gain in adults. Public Health Nutr 2009;12:1-11.
35. Anderson RA, Evans ML, Ellis GR, Graham J, Morris K, Jackson SK et al. The relationships between post-prandial lipaemia, endothelial function and oxidative stress in healthy individuals and patients with type 2 diabetes. Atherosclerosis 2001;154: 475-483. (Pubitemid 32146622)
36. Groot PH, van Stiphout WA, Krauss XH, Jansen H, van Tol A, van Ramshorst E et al. Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. Arterioscler Thromb 1991;11:653-662.
37. Bessesen DH, Vensor SH, Jackman MR. Trafficking of dietary oleic, linolenic, and stearic acids in fasted or fed lean rats. Am J Physiol Endocrinol Metab 2000;278: E1124-E1132. (Pubitemid 30439151)
38. Qasqas SA, McPherson C, Frishman WH, Elkayam U. Cardiovascular pharmacotherapeutic considerations during pregnancy and lactation. Cardiol Rev 2004;12:240-261. (Pubitemid 39121678)